U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726160) titled 'A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma' on June 30.
Brief Summary: A single-arm, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, and preliminary efficacy of KIV-318 Injection in patients with relapsed/refractory multiple myeloma.
Study Start Date: July 20
Study Type: INTERVENTIONAL
Condition:
Relapse and/or Refractory Multiple Myeloma
Intervention:
BIOLOGICAL: KIV-318
In vivo BCMA-targeted CAR-T KIV-318 Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Publ...